Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Current Deferred Revenue (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Current Deferred Revenue for 17 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 16.99% to $23.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.0 million through Dec 2025, up 16.99% year-over-year, with the annual reading at $23.0 million for FY2025, 16.99% up from the prior year.
  • Current Deferred Revenue hit $23.0 million in Q4 2025 for Integra Lifesciences Holdings, up from $22.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $23.0 million in Q4 2025 to a low of $5.3 million in Q1 2022.
  • Historically, Current Deferred Revenue has averaged $11.9 million across 5 years, with a median of $10.8 million in 2025.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 54.97% in 2022 and later surged 209.92% in 2023.
  • Year by year, Current Deferred Revenue stood at $11.9 million in 2021, then crashed by 39.29% to $7.3 million in 2022, then soared by 124.07% to $16.3 million in 2023, then increased by 21.03% to $19.7 million in 2024, then grew by 16.99% to $23.0 million in 2025.
  • Business Quant data shows Current Deferred Revenue for IART at $23.0 million in Q4 2025, $22.3 million in Q3 2025, and $11.1 million in Q2 2025.